Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Randy Milby Insider Profile
11 Followers
Randy Milby, CEO, Director at Cormedix, holds 17.53K shares in Tharimmune (Ticker: THAR), holds 403.27K shares in Cormedix (Ticker: CRMD). Most recently, Randy Milby Bought ― shares of Tharimmune on Dec 20, 2024 for an estimated value of 9.75K.
Profitable Transactions
11 out of 32 Profitable Transactions
Average Return
-23.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Randy Milby
Randy Milby's Trading History
Cormedix
Aug 10, 2016
CEO, Director
Uninformative Buy
82.50K
$3.46M
Tharimmune
Dec 20, 2024
CEO, Director
Informative Buy
9.75K
$36.30K
List of latest transactions for each holding click on a transaction to see Randy Milby's performance on stock
You May Also Like
Randy Milby insider profile FAQ
What is the percentage of profitable transactions made by Randy Milby?
The percentage of profitable transactions made by Randy Milby is 34%.
What is the average return per transaction made by Randy Milby?
The average return per transaction made by Randy Milby is -23.00%.
What stocks does Randy Milby hold?
Randy Milby holds: CRMD, THAR stocks.
What was Randy Milby’s latest transaction?
Randy Milby latest transaction was an Informative Buy of $9.75K.
What was Randy Milby's most profitable transaction?
Randy Milby’s most profitable transaction was an Informative Buy of CRMD stock on October 17, 2014. The return on the trade was 63.70%.
What is Randy Milby's role in Cormedix?
Randy Milby's role in Cormedix is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.